WuXi STA to build second US pharma manufacturing site at Middletown

Facility is expected to come online in 2024 and will feature testing laboratories, manufacture of active pharmaceutical ingredients and manufacture and packaging of solid dosage pharmaceuticals and sterile products

According to local reports that surfaced last week, the CDMO was seeking $19 million of funding for the project.

The new facility, which is expected to come online in 2024, will feature space for testing laboratories, manufacture of active pharmaceutical ingredients (APIs) and manufacture and packaging of solid dosage pharmaceuticals and sterile products.

Situated on a 190-acre campus, Middletown will become WuXi STA’s second site in the US – the first is a smaller site in San Diego -- and will contain state-of-the-art pharmaceutical clinical and commercial manufacturing capabilities.

WuXi STA currently provides pharmaceutical development and manufacturing solutions, covering small molecules and novel molecular modalities such as oligonucleotide, peptide and various complex conjugates.

Wuxi STA said it expects to create around 500 new full-time jobs at the Middletown site by 2026.